The Impact of BMI on the Effect of Biologic Agents for Severe Asthma - PubMed
a day ago
- #severe asthma
- #BMI
- #biologic agents
- Higher BMI is associated with higher prevalence and incidence of severe asthma.
- Biologic agents like mepolizumab, benralizumab, dupilumab, reslizumab, and tezepelumab are used for severe asthma treatment.
- Mepolizumab shows better outcomes in patients with BMI < 30 kg/m², while higher BMI is linked to failure in achieving clinical remission.
- Benralizumab improves respiratory symptoms and reduces asthma exacerbation rates in patients with BMI ≤ 35 kg/m², but not in those with BMI > 35 kg/m².
- Dupilumab is equally effective across all BMI levels.
- Reslizumab is effective across different BMI levels, but effectiveness decreases in patients with high BMI.
- No studies were found on tezepelumab's effectiveness in relation to BMI.
- More research is needed to evaluate biologic therapies in severe asthma patients with comorbid obesity.